Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy

Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients. Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy. Patients and Methods: In this study, 160 HIV patients und...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Foroogh Sabzghabaei, Afsaneh Sedighi, Raziyeh Shahi, Vahid Mahmoodi, Jahanbakhsh Khamseh, Neda Rahimian
Formato:	article
Lenguaje:	EN
Publicado:	Society of Diabetic Nephropathy Prevention 2022
Materias:	human immunodeficiency virus tenofovir nephropathy Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/fd6d9e8aa734486698b64618205a03e6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd6d9e8aa734486698b64618205a03e6
record_format	dspace
spelling	oai:doaj.org-article:fd6d9e8aa734486698b64618205a03e62021-11-17T08:15:00ZPrevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy2345-420210.34172/npj.2022.11https://doaj.org/article/fd6d9e8aa734486698b64618205a03e62022-01-01T00:00:00Zhttps://jnephropharmacology.com/PDF/npj-10414https://doaj.org/toc/2345-4202Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients. Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy. Patients and Methods: In this study, 160 HIV patients under tenofovir therapy were enrolled and the prevalence of nephropathy and proximal tubule disorder was determined and compared. Results: We found, the proximal tubule involvement in 25%, 6.8%, 2.2% and 0% in first year, 2–5 years , 6–10 years and 11–18 years of disease involvement respectively, (P = 0.02). The mean glomerular filtration rate (GFR) diminution was 2.15%, 10.53%, 12.6% and 17.79%, in the first, 2–5, 6–10, and 11–18 years, respectively, again showing a significant difference between years (P = 0.02). Proteinuria was seen in 13.1% of patients. Conclusion: We concluded that GFR diminution and proximal tubule involvement are common and important to be managed in HIV-positive patients under tenofovir therapy, and discontinuation of drug has no positive effect on GFR.Foroogh SabzghabaeiAfsaneh SedighiRaziyeh ShahiVahid MahmoodiJahanbakhsh KhamsehNeda RahimianSociety of Diabetic Nephropathy Prevention articlehuman immunodeficiency virustenofovirnephropathyTherapeutics. PharmacologyRM1-950Diseases of the genitourinary system. UrologyRC870-923ENJournal of Nephropharmacology, Vol 11, Iss 1, Pp e11-e11 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	human immunodeficiency virus tenofovir nephropathy Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923
spellingShingle	human immunodeficiency virus tenofovir nephropathy Therapeutics. Pharmacology RM1-950 Diseases of the genitourinary system. Urology RC870-923 Foroogh Sabzghabaei Afsaneh Sedighi Raziyeh Shahi Vahid Mahmoodi Jahanbakhsh Khamseh Neda Rahimian Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
description	Introduction: Tenofovir is a common therapy in human immunodeficiency virus (HIV) patients. Objective: This study was carried out to determine the prevalence of nephropathy and proximal tubule disorder in HIV patients under tenofovir therapy. Patients and Methods: In this study, 160 HIV patients under tenofovir therapy were enrolled and the prevalence of nephropathy and proximal tubule disorder was determined and compared. Results: We found, the proximal tubule involvement in 25%, 6.8%, 2.2% and 0% in first year, 2–5 years , 6–10 years and 11–18 years of disease involvement respectively, (P = 0.02). The mean glomerular filtration rate (GFR) diminution was 2.15%, 10.53%, 12.6% and 17.79%, in the first, 2–5, 6–10, and 11–18 years, respectively, again showing a significant difference between years (P = 0.02). Proteinuria was seen in 13.1% of patients. Conclusion: We concluded that GFR diminution and proximal tubule involvement are common and important to be managed in HIV-positive patients under tenofovir therapy, and discontinuation of drug has no positive effect on GFR.
format	article
author	Foroogh Sabzghabaei Afsaneh Sedighi Raziyeh Shahi Vahid Mahmoodi Jahanbakhsh Khamseh Neda Rahimian
author_facet	Foroogh Sabzghabaei Afsaneh Sedighi Raziyeh Shahi Vahid Mahmoodi Jahanbakhsh Khamseh Neda Rahimian
author_sort	Foroogh Sabzghabaei
title	Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
title_short	Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
title_full	Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
title_fullStr	Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
title_full_unstemmed	Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
title_sort	prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy
publisher	Society of Diabetic Nephropathy Prevention
publishDate	2022
url	https://doaj.org/article/fd6d9e8aa734486698b64618205a03e6
work_keys_str_mv	AT forooghsabzghabaei prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy AT afsanehsedighi prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy AT raziyehshahi prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy AT vahidmahmoodi prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy AT jahanbakhshkhamseh prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy AT nedarahimian prevalenceofnephropathyandproximaltubuledisorderinhumanimmunodeficiencyviruspatientsundertenofovirtherapy
_version_	1718425840962764800

Prevalence of nephropathy and proximal tubule disorder in human immunodeficiency virus patients under tenofovir therapy

Ejemplares similares